Nifty 50
- Max Healthcare₹991.0543.95 (4.64%)
- Tata Motors PV₹267.05-20.35 (-7.08%)
- Bharti Airtel₹2,157.1051.10 (2.43%)
- Tata Steel₹183.91-2.77 (-1.48%)
- ITC₹291.906.90 (2.42%)
- InterGlobe Aviation₹5,537.80-49.50 (-0.89%)
- Tata Consumer ₹1,101.9022.90 (2.12%)
- Bajaj Finance₹1,108.05-8.95 (-0.80%)
- Asian Paints₹2,603.2053.20 (2.09%)
- Coal India₹400.55-2.95 (-0.73%)
- Eternal₹370.506.85 (1.88%)
- Hindalco Industries₹937.45-6.15 (-0.65%)
- Kotak Mahindra Bank₹496.758.20 (1.68%)
- JSW Steel₹1,340.20-7.80 (-0.58%)
- Apollo Hospitals₹8,660.50134.50 (1.58%)
- Adani Enterprises₹2,673.30-14.70 (-0.55%)
- SBI₹1,095.9015.90 (1.47%)
- Bajaj Finserv₹1,855.10-9.90 (-0.53%)
- Nestle₹1,281.1017.90 (1.42%)
- Bajaj Auto₹10,807-43.00 (-0.40%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Alembic Pharma Receives USFDA Approval for Lung Cancer Drug
Authored By PTI | Published at: Nov 16, 2026 09:15 AM IST

Open Free Demat Account
New Delhi: Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Binimetinib tablets for treatment of lung cancer.
The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product, Mektovi Tablets (15 mg), of Array BioPharma Inc, the company said in a regulatory filing on Saturday.
Alembic is eligible for 180 days of generic drug exclusivity for Binimetinib Tablets, 15 mg and 45 mg, as it was one of the first ANDA applicants for the 15 mg strength and the sole first applicant for the 45 mg strength to submit a substantially complete ANDA with a paragraph IV certification, the filing said.
Binimetinib is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma and non-small cell lung cancer with a BRAF V600E mutation, it said.
According to IQVIA, Binimetinib tablets have an estimated market size of USD 282 million for the 12 months ending September 2026, the filing noted.
With this approval, Alembic has a cumulative total of 248 ANDA approvals from the USFDA, comprising 230 final approvals and 18 tentative approvals.
(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)
Disclaimer
The information shared here is intended solely for informational and educational purposes and does not constitute investment recommendations. While we practice strict due diligence in curating daily market data, readers must perform independent research before trading. To flag any real-time data discrepancies or content concerns, please write to us at content@hdfcsec.com.
More APLLTD News
Open Free Demat Account
₹1,054.35
By signing up I certify terms, conditions & privacy policy
Join Us
Add as preferred source on Google


















